FDA: Roflumilast Foam NDA Accepted for Seborrheic Dermatitis

Press/Media

Period	1 Apr 2023

Media coverage

Title	FDA: Roflumilast Foam NDA Accepted for Seborrheic Dermatitis
Media name/outlet	Drug Topics (MJH)
Country/Territory	United States
Date	1/04/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=6827-MFH1-JCXN-V387-00000-00
Persons	Peter Lio